Scientific Advisors

Jian-Ming Xu. M.D,

Member Scientific Advisory Board

Jian-Ming Xu, M.D, director of the Department of Gastroenterology of the Fifth Medical Center of the PLA General Hospital, and an expert in oncology of the Chinese digestive system, is one of the main researchers of clinical research on innovative drugs in China. He is currently the chairman of the gastrointestinal pancreatic neuroendocrine cancer professional committee of the Chinese Society of Clinical Oncology, the vice chairman of the Cancer Research Committee of the China Research Hospital Association, and the deputy director of the Cancer Big Data and Real World Research Committee of the China Anti-Cancer Association.

As an expert in clinical research and new drug reviews of the State Drug Administration. The precise medical research of gastrointestinal tumors based on liquid biopsy and molecular proteomics research to predict the efficacy of gastric cancer have been recognized by experts at home and abroad. He has outstanding research in PD-1 / PD-L1 immune monoclonal antibody treatment of gastric cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, neuroendocrine cancer, and clinical research and translational medicine of anti-VEGFR targeted drugs for neuroendocrine tumors. contribution. From 2015 to 2019, he led more than 40 national multi-center clinical studies.

Since 2015, the first author / corresponding author has published 40 papers, including 20 SCI papers, with a single impact factor of 24.008 points and a total impact factor of 122.462 points. He wrote the "Chinese Neuroendocrine Tumor Expert Consensus" and participated in the "Diagnosis and Treatment of Primary Liver Cancer (2019 Edition)" and "Diagnosis and Treatment of Colorectal Cancer (2020 Edition)" formulated by the National Health and Health Commission Development. Published monograph "Stomach Cancer".

Fan Pan. M.D,

Member Scientific Advisory Board

Fan Pan, M.D, professor and research scientist of Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine.
Medicine and public health have long been Johns Hopkins' strengths, and its medical school is equally as famous as Harvard's. Johns Hopkins is ranked third globally in biomedicine and life sciences by the Times higher education supplement. Dr. Pan has devoted himself to the research on tumor immunology for more than 10 years up to now, he has made outstanding contributions on elucidating the control of development, linkage stability and function of T cell subtypes.

As an expert in molecular regulatory mechanism of T cells of tumor immunology, Dr. Pan has a long-term research on Treg and Th17, two cell populations that play a crucial role in immune control and immune pathology. Dr. Pan explained the important role of transcription factor Eos in mediated gene inhibition of foxp3 which published in journal Science in 2009. This project has branched into an active investigation of the role played by a particular microRNA, miR17 in Eos gene regulation (Immunity, 2016).
Subsequently, Dr. Pan published a paper in journal Cell in 2011 about the discovery that oxygen sensor molecule HIF-1alpha is the key regulator for balancing the pro-inflammatory Th17 cell population and immune suppressive Treg cell population. Dr. Pan Fan cooperated with professor Li Bin from Chinese Academy of Sciences discovered the importance of Stub1 enzyme to remove Foxp3 protein from T cells under inflammatory stress, which is published in Immunity In 2013. In 2016, his research group identified that a particular microRNA, miR17, plays a critical role in Eos gene regulation and Treg function (Immunity,2016). Recently, his lab has demonstrated that YAP is essential for Treg-mediated suppression of antitumor immunity (Cancer Discovery, 2018). In addition, his lab also revealed that Traf6 is a critical E3 ligase for Foxp3-meiated regulatory T-cell function through K63-linked ubiquitination. (EMBO J, 2019).